A carregar...
The pharmacokinetics and safety of darapladib in subjects with severe renal impairment
AIM: Darapladib is a potent and reversible orally active inhibitor of lipoprotein-associated phospholipase A(2) (Lp-PLA(2)). The aim of the study was to assess the effects of severe renal impairment on the pharmacokinetics and safety/tolerability of darapladib compared with normal renal function. ME...
Na minha lista:
| Publicado no: | Br J Clin Pharmacol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons, Ltd
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4594701/ https://ncbi.nlm.nih.gov/pubmed/25953363 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12661 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|